Tag
In a population-based Alberta cohort, women with incident stage 5 CKD lost the usual female survival advantage: younger women had substantially higher excess mortality than men and were less likely to receive transplants or dialysis, indepe
A personalized clinical decision support tool increased 30‑day reinitiation of ACE inhibitors or ARBs from 13% to 18% among veterans with CKD; benefits were modest and limited by population and implementation factors.
The GBD 2023 analysis estimates 788 million adults living with chronic kidney disease in 2023, rising since 1990, with CKD a top-10 cause of death and a major contributor to cardiovascular mortality. Urgent action on screening, prevention,
A pooled analysis of 58,816 participants shows SGLT2 inhibitors lower kidney disease progression, AKI, hospitalizations, and mortality across diabetes status and albuminuria levels, with larger absolute kidney benefits where UACR ≥200 mg/g.
A SMART‑C meta‑analysis of 70,361 participants shows SGLT2 inhibitors reduce CKD progression and kidney failure across eGFR and albuminuria strata, including stage 4 CKD and low albuminuria.
Dapagliflozin reduces left ventricular mass index in chronic kidney disease patients, revealing a key mechanism for cardioprotective effects of SGLT2 inhibitors and highlighting early treatment benefits.
This randomized trial evaluates the safety and efficacy of everolimus combined with low-dose tacrolimus versus standard immunosuppression in children 6 months post-heart transplant, highlighting comparable rejection rates, improved kidney f
This study demonstrates that statin therapy effectively reduces cardiovascular risk and all-cause mortality in older adults with chronic kidney disease and hypercholesterolemia, without increasing major adverse events, even in very elderly
This study reveals that adherence to the American Heart Association diet significantly reduces CKD progression risk from cardio-metabolic disorders, underscoring its role in early intervention strategies.
Steroidal mineralocorticoid receptor antagonists show minimal impact on cardiovascular mortality in dialysis patients, with limited safety concerns and evidence gaps in subgroups and non-steroidal agents.
Reduced left ventricular ejection fraction (LVEF) adversely affects survival and myocardial infarction risk in patients with chronic kidney disease undergoing percutaneous coronary intervention, despite no significant difference in overall
This analysis of the AZALEA-TIMI 71 trial reveals that abelacimab, a novel factor XI inhibitor, significantly reduces bleeding risk versus rivaroxaban in atrial fibrillation patients, regardless of kidney function, suggesting its promise fo
A phase 2 randomized trial in CKD patients shows lubiprostone preserves renal function by modulating gut microbiota polyamine pathways and improving mitochondrial health, independent of uremic toxin levels, offering a novel therapeutic aven
Uremia, the deadly end-stage of kidney disease, is increasingly diagnosed in younger adults. Early detection and lifestyle changes can prevent progression. This article explores risk factors, symptoms, diagnosis, treatment options, and prev
A large real-world study shows that SGLT2 inhibitors significantly slow kidney function decline and improve albuminuria compared with other glucose-lowering drugs in type 2 diabetes patients with chronic kidney disease.
Cisplatin chemotherapy is associated with predictable kidney function decline, with pre-treatment eGFR effectively forecasting chronic kidney disease risk post-treatment. Simple models outperform complex approaches, offering practical clini
Complementary and alternative medicine (CAM) use is prevalent in chronic kidney disease (CKD), with 43% of patients globally employing CAM modalities. Nutritional supplements, mind-body practices, and traditional medicines are widely used,
Perioperative nitric oxide administration in CKD patients undergoing cardiac surgery significantly reduces acute kidney injury incidence and preserves renal function, while demonstrating safety and additional benefits against postoperative
A comprehensive proteomic analysis from the ARIC study identifies plasma proteins linking kidney dysfunction to incident heart failure, highlighting potential biomarkers and therapeutic targets for HF prevention in CKD patients.
The NUDGE-CKD trial found that electronic letter-based nudges to patients with chronic kidney disease and their general practitioners did not significantly improve initiation of guideline-recommended medications over usual care.
